Adagio Therapeutics, Inc.: Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants
Data to be presented at the 2021 ISIRV-WHO Virtual ConferenceWALTHAM, Mass., Oct. 19, 2021data from the company's ongoing Phase 1 trial of ADG20 in healthy participants. "These new variant data further